SANIOS Stock Overview
A clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, Germany, Denmark, the United Kingdom, and Mexico. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Saniona AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 3.84 |
| 52 Week High | SEK 0 |
| 52 Week Low | SEK 0 |
| Beta | 0.99 |
| 11 Month Change | 0% |
| 3 Month Change | -1.98% |
| 1 Year Change | n/a |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -86.58% |
Recent News & Updates
Recent updates
Shareholder Returns
| SANIOS | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | 1.5% | 2.2% |
| 1Y | n/a | -17.9% | 8.8% |
Return vs Industry: Insufficient data to determine how SANIOS performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how SANIOS performed against the UK Market.
Price Volatility
| SANIOS volatility | |
|---|---|
| SANIOS Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 10.2% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: SANIOS has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine SANIOS's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 22 | Thomas Feldthus | www.saniona.com |
Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, Germany, Denmark, the United Kingdom, and Mexico. It also develops medicines modulating ion channels. The company’s products include Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is Phase 2b clinical trial for the treatment of hypothalamic obesity and Prader-Willi syndrome.
Saniona AB (publ) Fundamentals Summary
| SANIOS fundamental statistics | |
|---|---|
| Market cap | SEK 537.28m |
| Earnings (TTM) | -SEK 81.81m |
| Revenue (TTM) | SEK 24.88m |
21.6x
P/S Ratio-6.6x
P/E RatioIs SANIOS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SANIOS income statement (TTM) | |
|---|---|
| Revenue | SEK 24.88m |
| Cost of Revenue | SEK 5.50m |
| Gross Profit | SEK 19.38m |
| Other Expenses | SEK 101.19m |
| Earnings | -SEK 81.81m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 28, 2024
| Earnings per share (EPS) | -0.74 |
| Gross Margin | 77.91% |
| Net Profit Margin | -328.83% |
| Debt/Equity Ratio | 574.8% |
How did SANIOS perform over the long term?
See historical performance and comparison